1-Corrado A, Sanpaolo ER, Di Bello S, Cantatore, FP.

Osteoblast as a target of
anti-osteoporotic treatment. J Postgrad Med. 2017 Aug;129(8):858–65

2- McCadden L, Leonard CG, Primrose WJ. Bisphosphonate-induced

osteonecrosis of the ear canal: our experience and a review of the literature. J
Laryngol otol. 2018 Feb; 132(04):372–74

3-Calvo CJ, Bágan DL, Pastor CMD, Campos FC, Rueda CIDA,González CCMI,
et al.Rev de la SVR.2015; 6(2):19-22

4- Radominski SC, Bernardo W, Paula AP de, Albergaria B, Moreira C,

Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da
osteoporose em mulheres na pós‐menopausa. Rev Bras Reumatol. 2017
Jun;57:452–66.

5-Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of

osteoporosis. BMJ. 2015 Sept;351:h3783.

6-Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ. Population-
based study of survival after osteoporotic fractures. Am J Epidemiol. 1993
May;137(9):1001–5.

7-Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime
osteoporosis impact. Arch Intern Med. 1991 Oct;151(10):2026–32

8-Arboleya L, Alperi M, Alonso S. Adverse effects of bisphosphonates. Reum

Clínic (English Edition).2011 Jan;7(3):189–97.

9-Maruotti N, Corrado A, Neve A, Maruotti, N, Cantatore FP. Bisphosphonates:

effects on osteoblast. Eur J Clin Pharmacol. 2012 Jul;68(7):1013-18

10-Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells
in vitro. Bone and Mineral.1994 Jan;26(2):95–107.

11-Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the

maturation of normal human osteoblasts. J Endocrinol Invest. 2002
Jun;25:539–46.

12- Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of

the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010
Aug;136(8):1117–24

13- Izquierdo CM, Oliveira MG, Weber JBB. Terapêutica com bisfosfonatos:
implicações no paciente odontológico – revisão de literatura. 2011;16(3):6.

14- Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al.
Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and
its relationship to teeth extractions. Study of 20 cases. Oral Oncol. Mar
2006;42(3):327–9.
15- Lin T-C, Yang C-Y, Kao Yang Y-H, Lin S-J. Incidence and risk of
osteonecrosis of thjaw among the Taiwan osteoporosis population. Osteoporos
Int. 2014 May;25(5):1503–11

16- Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the
American Society for Bone and Mineral Research. J Bone Miner Res. 2007
Oct;22:1479-91

17- Regev E, Lustmann J, Nashef R. Atraumatic teeth extraction in

bisphosphonate-treated patients. J Oral Maxillofac Surg. 2008 Jun;66(6):1157–
61

18-Cremers SCLM, Pillai G, Papapoulos SE.

Pharmacokinetics.Pharmacodynamics of bisphosphonates: use for optimisation
of intermittent therapy for osteoporosis. Clin Pharmacokinet. 2005;44(6):551–
70.

19-Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of
bisphosphonates: similarities and differences and their potential influence on
clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733–59.

20- Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, et
al. Postmenopausal osteoporosis treatment with antiresorptives: effects of
discontinuation or long-term continuation on bone turnover and fracture risk--a
perspective. J Bone Miner Res. 2012 May;27(5):963–74.

21- Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J, et al.

Risk of serious atrial fibrillation and stroke with use of bisphosphonates:
evidence from a meta-analysis. Chest. 2013 Oct;144(4):1311–22

22- Sadowski CA, Spencer T, Yuksel N. Use of Oral Bisphosphonates by Older

Adults with Fractures and Impaired Renal Function. Can J Hosp Pharm.
2011;64(1):36–41

Figura 3 -Cardona F, Bagán JV, Sáinz E, Figuerido J, Giner F, Vidán FJ.

Osteonecrosis de los maxilares por bisfosfonatos: Actualización y puesta al día.
Anales del Sistema Sanitario de Navarra. 2009 Dec;32(3):423–37.